TECP
DFTX

Trails Edge Capital Partners’s Definium Therapeutics DFTX Stock Holding History

Trails Edge Capital Partners’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,738,110
Closed -$32.9M – 37
2026
Q1 		$32.9M Sell
1,738,110
-830,000
-32% -$14.1M 7.53% 2
2025
Q4 		$34.4M Buy
+2,568,110
New +$31.8M 8.5% 2

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Trails Edge Capital Partners's DFTX Position: Q2 2026 in Review

Trails Edge Capital Partners sold out of Definium Therapeutics (DFTX) in Q2 2026, closing a stake of 1,738,110 shares — an estimated $32.9M sold.

Trails Edge Capital Partners first reported a position in DFTX in Q4 2025 and held it in 2 quarters. The position peaked at $34.4M in Q4 2025. 361 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Trails Edge Capital Partners reported no remaining Definium Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Trails Edge Capital Partners sold 1,738,110 Definium Therapeutics shares in Q2 2026, an estimated $32.9M.
  • Trails Edge Capital Partners first reported a position in Definium Therapeutics in Q4 2025 and held it in 2 quarters.
  • Trails Edge Capital Partners's Definium Therapeutics position peaked at $34.4M in Q4 2025.
  • 361 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Trails Edge Capital Partners's 13F filing for Q2 2026, filed 14 Aug 2026.